Prostate cancer is the most common non-cutaneous malignancy in American men. 1 One in six men in the United States will be diagnosed with this disease within his lifetime. 2 The vast majority of early stage prostate cancer presents as adenocarcinoma, and radical prostatectomy is largely curative for early stage disease. However, radical prostatectomy has the potential to negatively impact quality of life.
Therefore, the relatively conservative approach of "watchful waiting"
is appropriate for select patient populations. Most men with local or regional prostate cancer are still alive 15 years after treatment, and the overall 5-year survival rate for patients with metastatic disease at the time of diagnosis approaches 30%. 1, 3, 4 However, advanced metastatic prostate cancer, whether at initial diagnosis or after recurrence of previously treated disease, necessitates aggressive treatment.
Due to the central role of androgen receptor (AR) signaling in prostate cancer progression, androgen deprivation therapy (ADT) is widely used for the treatment of metastatic disease. 4 Approaches for ADT include AR antagonism (with bicalutamide or enzalutamide)
targeting the hypothalamic-pituitary axis (with gonadotropin releasing hormone agonists and antagonists), and, most recently, blockade of androgen synthesis (with abiraterone). These drugs are commonly used to modulate AR activity via blockade or reduction of androgen levels in patients presenting with locally advanced, metastatic and/or recurrent disease, including in the adjuvant setting upon a finding of sentinel lymph node involvement. 3 Currently, bicalutamide, enzalutamide, and abiraterone are commonly used, but these have been correlated with an increase in the development of therapy-resistant castrate-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). [5] [6] [7] Both CRPC and NEPC represent a terminal stage of disease with limited treatment options, as both are resistant to ADT. Patients who develop these phenotypes have drastically reduced survival rates and more aggressive metastasis. 2, 8, 9 While mutation and amplification of AR are common mechanisms associated with resistance to ADT, expression of constitutively active alternative splice variants of the AR is also implicated. 10, 11 Emergence of resistance, which can be due to expression of such splice variants, mediates a return to active disease, but also offers targets for future drug development. 12 For example, Vav3, a guanine nucleotide exchange factor which activates Rho family proteins, enhances nuclear translocation of both the full length AR 13 as well as AR splice variant AR-V7, 14, 15 indicating that this resistance mechanism is critically tied to Rho family proteins and may be targeted by altering Rho activity.
Rho proteins, and other related proteins such as Rac1, Cdc42, and Rab proteins, are small GTPases that are post-translationally modified via geranylgeranylation, which enables membrane localization ( Figure 1A ). Geranylgeranylation of Rho family proteins occurs with the addition of the isoprenoid geranylgeranyl pyrophosphate (GGPP)
by the enzyme GGTase I ( Figure 1A -B). Digeranyl bisphosphonate (DGBP, Figure 1C ), a potent, selective and competitive inhibitor of geranylgeranyl pyrophosphate synthase (GGPS1), facilitates the study of these pathways. 16 DGBP reduces GGPP levels within cells and has also been shown to induce apoptosis, 17 stimulate autophagy in prostate cancer cells, 18 reduce breast cancer cell migration, 19 and modulate osteoblast differentiation 20 by reducing post-translational geranylgeranylation of proteins such as Rho and related family members. Most recently, reductions in metastatic behavior in two animal models of prostate cancer have been observed. 21, 22 In the present study, inhibition of GGPS1 in the neuroendocrine differentiation of prostate cancer was examined to test the hypothesis that geranylgeranylation, and thus activity of GGPS1, is required for the process of neuroendocrine differentiation to occur. The effects of inhibiting GGPS1 on the localization and signaling of AR, the most common driver of prostate cancer growth, were also observed. 
| Immunofluorescence
Cells were plated onto coverslips at 4000 cells/mL and allowed to attach overnight before treatment. After treatment with abiraterone, DGBP, and/or GGOH for the stated amount of time, cover slips were fixed with 3% paraformaldehyde/2% sucrose fixative solution for 
| Statistics
All experiments were carried out in triplicate or quadruplicate.
Densitometry of Western blotting data was normalized to β-tubulin, then analyzed via two way ANOVA (analysis of variance) with multiple comparisons (Sidak's post hoc). Imaging results were quantified by a blinded researcher, then analyzed with one way ANOVA. Figure 2A ). In the Beltran cohort, samples from patients with CRPC with either adenocarcinoma or NEPC phenotypes highly expressed a expression data ( Figure 2B ). 31 These included GGPS1, which synthesizes geranylgeranyl pyrophosphate (and is the target for DGBP), GGT1, which geranylgeranylates Rho, Rac, and Cdc42, and a number of isoprenylated proteins themselves, including both Rho and Rab family proteins. These proteins are essential for cellular motility, cell cycle regulation, and differentiation processes, all of which are significant in prostate cancer progression. [32] [33] [34] High expression of these enzymes suggests that more of these proteins are post-translationally modified and active in patient tumors. Expression of GGT2, the Rab geranylgeranyl transferase, was not significantly altered.
| DGBP alters AR nuclear localization and AR-responsive reporter activity
In order to understand how DGBP may affect prostate cancer progression, this compound's effect on AR activity was first determined.
According NKX3-1, prostate specific homeobox gene; TMPRSS2, transmembrane protease, serine 2) were also significantly elevated in R1881 treated cells over controls in a manner which was reduced with DGBP, back to baseline levels in all genes but FKBP2 ( Figure 3B , P < 0.05 with Tukey's multiple comparisons). The blunted effect on FKBP2 may be attributed to this protein's regulation by another nuclear receptor, the glucocorticoid receptor, 35 or by epigenetic regulation processes. 36 However, AR protein expression is not significantly altered over this time frame
(Supplementary Figure S1B) . To understand why AR-responsive reporter activity is reduced despite ample AR presence, immunofluorescence was employed to examine AR cellular localization. In LNCaP 
| DGBP blocks the development of the NEPC phenotype
Since DGBP could reduce nuclear localization and transcriptional activity of AR, we were interested in its effects on the development of the NEPC phenotype. Literature suggests that the use of androgen deprivation therapy with the competitive AR antagonist, enzalutamide, induces this phenotype in patients and in culture, as does the use of prolonged in vitro culture in charcoal stripped SR media. 37 This process is known to be related to blockade of AR signaling within the cell.
Expression levels of the NEPC markers NSE, a neuronal and neuroendocrine enolase, and CgA, a neuroendocrine secretory 
| GGOH can induce expression of NEPC markers
The addition of geranylgeraniol (GGOH) was used to determine if the effect of DGBP on neuroendocrine markers was due to blockade of geranylgeranylation or a nonspecific effect of this compound. GGOH is the alcohol of GGPP, a key isoprenoid intermediate, which is used to geranylgeranylate proteins ( Figures 1A and 1B) . GGOH more readily penetrates the cell membrane than the pyrophosphate because of charge to mass ratios and can be converted to the pyrophosphate within the cell. Figures 5C and 5D ). In aggregate, results suggest that the effects of DGBP on neuroendocrine differentiation are due to its activity at GGPS1 and not off target effects.
| DISCUSSION
The current study indicates that geranylgeranylation of proteins is involved in development of the NEPC phenotype and suggests that These same authors had previously demonstrated that Rac1 activity was greater in androgen independent cell lines, 47 and that this activity was instrumental in down regulating the tumor suppressor p21
CIP1
. Another study examined clinical prostatectomy specimens and found that increased levels of Rac proteins (Rac1, Rac2, and Rac3) were associated with a decrease in disease-free survival. 48 Additional studies of Rac associated signaling implicates Rac as a crucial information integration point where enhanced signal strength leads to advanced disease, metastatic spread, and poor prognosis. 49, 50 Rac signaling is also linked to progression to the hormone resistant state by controlling communication between genotropic and non-genotropic signaling in the proliferation of prostate cancer cells. 51, 52 Along with these previous studies, this work underscores the potential importance of these small GTPases in prostate cancer progression. Future studies will further elucidate the role of these isoprenylated proteins in the development of NEPC. 
| CONCLUSION
In conclusion, drugs which target the processes of NEPC development and AR nuclear localization could prevent both tumor growth of normal prostate cancer and progression to CRPC. It is possible that the inhibition of GGPS1 via DGBP or similar compounds could potentially be used as an adjunct treatment with the standard of care for prostate cancer as a therapeutic agent in the future. Notably, a similar compound is well tolerated in a mouse model of prostate cancer, where it reduced tumor metastasis. 21, 22 This would suggest that this class of drugs has a safe therapeutic window which may be exploited for use in human cancer treatment after appropriate development.
As androgen deprivation therapy is commonly used to treat prostate adenocarcinoma, it is important to understand the relation- 
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